Abstract Details

Title Development of a Patient-centric Botulinum Toxin Response Scale (BTRS) Through Qualitative Analysis

Topic Movement Disorders

Presentation(s) P7 - Poster Session 7 (8:00 AM-9:00 AM)

Poster/Presentation
Number 16-013

Objective To develop a comprehensive, patient-centric Botulinum Toxin Response Scale (BTRS) by integrating qualitative patient feedback into a dynamic, digital survey tool, and to demonstrate the revised BTRS.

Background Tracking botulinum toxin (BTX) efficacy for neurological disorders is hampered by recall bias between appointments. We have previously developed a prototype version of the BTRS previously and aimed to refine and expand it with patient interviews.

Design/Methods Following Institutional Review Board approval, this prospective observational study recruited 30 patients receiving BTX for spasticity, dystonia, tremor, or sialorrhea at the University of Vermont Medical Center. Data were collected via a baseline REDCap survey and semi-structured interviews exploring treatment experiences. Interview transcripts underwent a rigorous thematic analysis using a large language model to identify key patient priorities. These themes directly guided the iterative development of a new, interactive weekly survey tool. We created a web-based version of the revised BTRS.

Results

Thematic analysis revealed five core themes: 1) the impact of BTX on quality of life, 2) significant logistical and financial barriers to care, 3) the "wear-off" effect of the treatment, 4) physical discomforts and side effects, and 5) the crucial role of the patient-provider relationship.

The digital survey was then modified based on the thematic analysis to address many unique conditions, with each featuring a specific questionnaire to capture the distinct goals and symptoms for that condition (e.g., tracking drooling for sialorrhea, range of motion for dystonia). The final tool also incorporates universal modules to monitor the treatment timeline, progress toward patient-defined functional goals, co-therapies, and overall satisfaction.

Conclusions The revised BTRS addresses patients’ perspectives, and its web-based implementation has the potential to serve as a patient reported outcome (PRO) measure via patient portals in electronic health record (EHR) systems.

Authors/Disclosures
Alaina Tyler PRESENTER	Miss Tyler has nothing to disclose.
Vivikta Iyer, MBBS	Dr. Iyer has nothing to disclose.
Cole Zweber	Mr. Zweber has nothing to disclose.
Deepak K. Gupta, MBBS (University of Vermont Medical Center)	The institution of Dr. Gupta has received research support from Department of Defense.
Lisa M. Deuel, MD (University of Vermont)	Dr. Deuel has nothing to disclose.
James T. Boyd, MD (University of Vermont Medical Center)	Dr. Boyd has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NeuroDerm . Dr. Boyd has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for InTrance. Dr. Boyd has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurocrine. Dr. Boyd has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Parkinson Study Group . The institution of Dr. Boyd has received research support from NIA/NIH. The institution of Dr. Boyd has received research support from Biotie . The institution of Dr. Boyd has received research support from vaccinex. The institution of Dr. Boyd has received research support from CHDI. The institution of Dr. Boyd has received research support from AbbVie. The institution of Dr. Boyd has received research support from Roche . The institution of Dr. Boyd has received research support from Revance . The institution of Dr. Boyd has received research support from NeuroDerm. The institution of Dr. Boyd has received research support from Neurocrine .

��ɫ��

��ɫ��